期刊文献+

汉黄芩素抑制PI3K/Akt/mTOR信号通路影响急性白血病HL-60细胞增殖 被引量:12

Effect of Wogonin on the Proliferation in Acute Myeloid Leukemia HL-60 Cell Through Inhibition of PI3K/Akt/mTOR Signaling Pathway
下载PDF
导出
摘要 探讨汉黄芩素对急性白血病HL-60细胞增殖及其可能的作用机制.以不同浓度(10,20,40,80,100μmol/L)的汉黄芩素分别作用于HL-60 24,48,72h后,采用MTT法检测其对细胞增殖活性的影响;台盼蓝拒染法观察汉黄芩素作用HL-60细胞48h后,对细胞活力的影响;Western blot法检测汉黄芩素对HL-60细胞中PI3K/AKT/mTOR和Raf/MEK/ERK信号通路中相关蛋白的表达.结果表明:汉黄芩素能够显著抑制HL-60细胞增殖,具有浓度依赖和时间依赖性.此外,汉黄芩素对PI3K/AKT/mTOR信号通路中p-PI3K、pAKT、mTOR和p-mTOR蛋白表达具有明显的抑制作用;对Raf/MEK/ERK信号通路中的MEK、ERK蛋白表达增加,抑制ERK1/2的磷酸化水平.汉黄芩素抑制HL-60细胞增殖和逆转耐药性,其作用机制可能与抑制PI3K/AKT/mTOR信号通路蛋白的表达和下调Raf/MEK/ERK信号通路中ERK磷酸化水平有关. The aim of this study is to investigate the inhibitory effect of wogonin on the proliferation of acute myeloid leukemia HL-60 cell and its underlying mechanism.HL-60 cells were treated with wogonin at different concentrations of 10-100μmol/L for 24-72 hours,respectively.MTT assay was performed to assess the cell proliferation.Trypan blue exclusion assay was used to determine cell viability.Western blot was adopted to analyze the cell proliferation related proteins expression of PI3 K/AKT/mTOR and Raf/MEK/ERK signaling pathway in HL-60 cells.The results showed that Wogonin obviously inhibited the viability of HL-60 cells in a dose dependent and time dependent manner,the IC50 value of wogonin for 24,48,72 hours was 40,30,15μmol/L,respectively.In addition,wogonin reduced the phosphorylation of PI3 K,AKT,mTOR in the HL-60 cells.Furthermore,wogonin suppressed of mTOR in the HL-60 cells to a varying degree which showed obvious concentration-dependent manner.In Raf/MEK/ERKsignaling pathway,wogonin increased the expression of MEK and ERK,but reduced the phosphorylation of ERK.In summary,our study results indicated that wogonin inhibited proliferation and reversed drug resistance,which were mediated by the inhibition of PI3 K/AKT/mTOR signaling pathway and down-regulation the phosphorylation of ERK inRaf/MEK/ERKsignaling pathway.
出处 《泉州师范学院学报》 2017年第6期1-5,共5页 Journal of Quanzhou Normal University
基金 福建省自然科学基金项目(2017J01856) 国家级大学生创新创业训练项目(201410399006) 泉州市科技计划项目(2011Z24)
关键词 汉黄芩素 HL-60细胞 细胞增殖 PI3K/Akt/mTOR信号通路 耐药性 Raf/MEK/ERK信号通路 Wogonin HL-60 proliferation PI3K/Akt/mTOR drug resistance Raf/MEK/ERK
  • 相关文献

参考文献2

二级参考文献24

  • 1Vincent A,Herman J,Schulick R. Pancreatic cancer[J].The Lancet,2011,(9791):607-620. 被引量:1
  • 2Zoncu R,Efeyan A,Sabatini DM. mTOR:from growth signal integration to cancer,diabetes and ageing[J].Nature Reviews Molecular Cell Biology,2011,(01):21-35. 被引量:1
  • 3Bellizzi AM,Bloomston M,Zhou XP. The mTOR pathway is frequently activated in ancreatic ductal adenocarcinoma and chronic pancreatitis[J].Applied Immunohistochemistry & Molecular Morphology,2010,(05):442-447. 被引量:1
  • 4Lebwohl D,Anak O,Sahmoud T. Development of everolimus,a novel oral mTOR inhibitor,across a spectrum of diseases[J].Annals of the New York Academy of Sciences,2013.14-32. 被引量:1
  • 5Piscazzi A,Costantino E,Maddalena F. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines[J].Journal of Clinical Endocrinology and Metabolism,2012,(06):E898-E906. 被引量:1
  • 6Josset E,Burckel H,Noel G. The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line[J].Anticancer Research,2013,(05):1845-1851. 被引量:1
  • 7Arnault JP,Mateus C,Escudier B. Skin tumors induced by sorafenib;paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS,TP53,and TGFBR1[J].Clinical Cancer Research,2012,(01):263-272. 被引量:1
  • 8Liu Y,Sun SY,Owonikoko TK. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells[J].Molecular Cancer Therapeutics,2012,(01):45-56. 被引量:1
  • 9Svejda B,Kidd M,Kazberouk A. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT[J].Cancer,2011,(18):4141-4154. 被引量:1
  • 10Liu AW,Cai J,Zhao XL. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth[J].Clinical Cancer Research,2011,(04):710-720. 被引量:1

共引文献37

同被引文献228

引证文献12

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部